Murtaza Mazhar, MD
Cardiovascular Disease · Galveston, TXNPI 1275915282
Payments from drug & device makers
Across 333 payments — averaging $154.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$15K
- Penumbra, Inc.$7K
- Medtronic$6K
- Abbott$6K
- Inari Medical, Inc.$4K
- Biotronik Inc.$4K
- plus $11K from 31 others
What the payments were for
- Grants$4,93310%
- Travel & lodging$11,61323%
- Food & beverage$20,06339%
- Education$2120%
- Other$14,79229%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 7 | $15,304 |
| Penumbra, Inc. | 42 | $6,764 |
| Medtronic | 19 | $5,596 |
| Abbott | 50 | $5,516 |
| Inari Medical, Inc. | 35 | $4,088 |
| Biotronik Inc. | 27 | $3,740 |
| Stryker | 8 | $2,068 |
| Boston Scientific | 33 | $1,736 |
| Abiomed | 16 | $1,649 |
| Shockwave Medical, Inc | 7 | $941 |
| Endologix LLC | 7 | $632 |
| Amgen | 14 | $437 |
| Imperative Care, Inc | 5 | $433 |
| Kestra Medical Technology Services, Inc. | 10 | $419 |
| Bard Peripheral Vascular, Inc. | 9 | $329 |
| Thrombolex, Inc. | 4 | $236 |
| Johnson & Johnson | 4 | $226 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $169 |
| Elutia, Inc. | 1 | $163 |
| Edwards Lifesciences | 2 | $161 |
| E.r. Squibb & Sons, L.L.C. | 3 | $144 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Heartflow, Inc. | 4 | $104 |
| Biosense Webster, Inc. | 1 | $102 |
| Nuwellis, Inc. | 1 | $101 |
| AstraZeneca | 1 | $97 |
| Pfizer | 1 | $86 |
| ZOLL Circulation Inc | 1 | $48 |
| Cook Medical LLC | 2 | $28 |
| Philips North America LLC | 1 | $28 |
| Novartis | 1 | $26 |
| Livanova USA, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $25 |
| ZOLL Respicardia, Inc. | 1 | $22 |
| Bayer | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Koya Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$15,040
- FLOWTRIEVER CATHETER, S$5,555
- CT THROMBECTOMY SYSTEM KIT$5,555
- Indigo System$4,301
- Ensite Cardiac Mapping System$3,219
- RUBY Coil$1,313
- Impella$1,257
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$794
- Torus Stent Graft System$421
- ENDOCROSS Device$421
- Assure WCD$327
- Penumbra System$291
- Repatha$271
- Cardiovascular- Research only$259
- EnSite Precision Cardiac Mapping System$212
- PRODIGY CATHETER$198
- GENERAL - THERAPIES$181
- Bashir Endovascular Catheter$178
- Diamondback Peripheral$167
- ECM Patch,Pouch$163
How this compares
$51,613 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 160 | $139,267 |
| XareltoRivaroxaban | 46 | $46,020 |
| BrilintaTicagrelor | 60 | $33,732 |
| EntrestoSacubitril/Valsartan | 23 | $22,028 |
| FarxigaDapagliflozin Propanediol | 13 | $9,247 |
| Amiodarone Hcl | 26 | $3,154 |
| ClopidogrelClopidogrel Bisulfate | 199 | $1,662 |
| Rosuvastatin Calcium | 156 | $1,476 |
| Metoprolol Succinate | 94 | $1,129 |
| Carvedilol | 168 | $1,068 |
| Losartan Potassium | 121 | $977 |
| Atorvastatin Calcium | 91 | $698 |
| Amlodipine Besylate | 157 | $693 |
| FenofibrateFenofibrate Nanocrystallized | 12 | $490 |
| Pantoprazole Sodium | 14 | $452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $139,267160 claims |
| Johnson & JohnsonXarelto | $226 | $46,02046 claims |
| AstraZenecaBrilinta, Farxiga | $97 | $42,97973 claims |
| NovartisEntresto | $26 | $22,02823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Galveston
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.